Compare J B Hunt Transport Services Inc (JBHT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Mesoblast Limited — how do they compare? J B Hunt Transport Services Inc trades at $227.97 (market cap $21.45B), while Mesoblast Limited trades at $14.28 (market cap $1.75B). The key difference: J B Hunt Transport Services Inc is far larger — about 12.3× Mesoblast Limited's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Mesoblast Limited for 14 Days on average.
| JBHT | MESO | |
|---|---|---|
Market Cap | $21.45B | $1.75B |
Volume | 1,028,680 | 239,027 |
Sector | Industrials | Health |
52-Week High | $298.41 | $20.96 |
52-Week Low | $137.09 | $13.19 |
Typical Hold Time | 45 Days | 14 Days |
Enterprise Value | $22.59B | $1.83B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $228.99, up 2.85% today, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $12.00B in 2025, with a net income margin of 4.98%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $289.40 price target, but news highlights ongoing securities class action investigations.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and legal risks pose headwinds. Investors should weigh earnings growth potential against cost pressures and litigation uncertainties for balanced risk-reward assessment.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
